JNJ

187.2

-0.94%↓

ABT

122.83

-0.61%↓

TMO

560.98

-1.24%↓

ISRG

538.56

+0.78%↑

DHR

213.85

-0.82%↓

JNJ

187.2

-0.94%↓

ABT

122.83

-0.61%↓

TMO

560.98

-1.24%↓

ISRG

538.56

+0.78%↑

DHR

213.85

-0.82%↓

JNJ

187.2

-0.94%↓

ABT

122.83

-0.61%↓

TMO

560.98

-1.24%↓

ISRG

538.56

+0.78%↑

DHR

213.85

-0.82%↓

JNJ

187.2

-0.94%↓

ABT

122.83

-0.61%↓

TMO

560.98

-1.24%↓

ISRG

538.56

+0.78%↑

DHR

213.85

-0.82%↓

JNJ

187.2

-0.94%↓

ABT

122.83

-0.61%↓

TMO

560.98

-1.24%↓

ISRG

538.56

+0.78%↑

DHR

213.85

-0.82%↓

Search

Quanterix Corp

Deschisă

SectorSănătate

5.27 -1.31

Rezumat

Modificarea prețului

24h

Curent

Minim

5.16

Maxim

5.44

Indicatori cheie

By Trading Economics

Venit

-9.5M

-30M

Vânzări

-5.9M

24M

Marjă de profit

-122.622

Angajați

471

EBITDA

-11M

-37M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+10.86% upside

Dividende

By Dow Jones

Următoarele câștiguri

11 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

50M

264M

Deschiderea anterioară

6.58

Închiderea anterioară

5.27

Sentimentul știrilor

By Acuity

50%

50%

142 / 373 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Quanterix Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 nov. 2025, 22:13 UTC

Câștiguri

Westpac Raises Dividend Despite 1% Slip in Annual Profit -- Update

2 nov. 2025, 21:23 UTC

Câștiguri

Westpac Raises Dividend Despite 1% Slip in Annual Profit

2 nov. 2025, 23:43 UTC

Market Talk

Gold Falls on Reports of China's Finance Ministry Ending Tax Incentive for Gold Sales -- Market Talk

2 nov. 2025, 23:34 UTC

Market Talk

Oil Rises as OPEC+ Signals Output-Increase Pause -- Market Talk

2 nov. 2025, 21:00 UTC

Câștiguri

Westpac Has Set Tech Overhaul Goals and Will Share Progress, CEO Says>WBC.AU

2 nov. 2025, 21:00 UTC

Câștiguri

Westpac Is Now Executing on Tech Overhaul, CEO Says>WBC.AU

2 nov. 2025, 21:00 UTC

Câștiguri

Westpac Has Completed Tech Overhaul's Discovery and Planning Phases, CEO Says >WBC.AU

2 nov. 2025, 20:55 UTC

Câștiguri

Westpac FY Australia Mortgage Lending Up 5% on Year>WBC.AU

2 nov. 2025, 20:55 UTC

Câștiguri

Westpac FY Institutional Lending Up 17% on Year>WBC.AU

2 nov. 2025, 20:55 UTC

Câștiguri

Westpac FY Business Lending Up 15% on Year>WBC.AU

2 nov. 2025, 20:46 UTC

Câștiguri

Westpac Expects Completion in 2H of FY 2026>WBC.AU

2 nov. 2025, 20:46 UTC

Câștiguri

Westpac Expects CET1 Capital Ratio to Rise by 20 Basis Points>WBC.AU

2 nov. 2025, 20:45 UTC

Câștiguri

Westpac: Sale Is at Slight Premium to Expected Gross Loan Value at Completion>WBC.AU

2 nov. 2025, 20:44 UTC

Câștiguri

Westpac Selling to Consortium Including KKR, Pimco and Pepper Money>WBC.AU

2 nov. 2025, 20:43 UTC

Câștiguri

Westpac Agrees to Sell A$21.4B Rams Mortgage Portfolio>WBC.AU

2 nov. 2025, 20:42 UTC

Câștiguri

Westpac FY Impairment Provisions A$4.99B Vs. A$5.10B>WBC.AU

2 nov. 2025, 20:41 UTC

Câștiguri

Westpac FY Net Profit Ex-Notable Items A$7.0B, Down 2% on Year>WBC.AU

2 nov. 2025, 20:40 UTC

Câștiguri

Westpac FY Customer Deposits A$723.0B Vs. A$673.6B>WBC.AU

2 nov. 2025, 20:39 UTC

Câștiguri

Westpac FY Total Loans A$851.85B Vs. A$806.77B>WBC.AU

2 nov. 2025, 20:37 UTC

Câștiguri

Westpac FY24 Impairment Charges 5 Bps of Loans Vs. 7 Bps in FY25>WBC.AU

2 nov. 2025, 20:37 UTC

Câștiguri

Westpac FY Operating Expenses A$11.92B Vs. A$10.94B>WBC.AU

2 nov. 2025, 20:37 UTC

Câștiguri

Westpac FY Non-Interest Income A$3.00B Vs. A$2.835B>WBC.AU

2 nov. 2025, 20:36 UTC

Câștiguri

Westpac FY Net Interest Income A$19.38B Vs. A$18.75B>WBC.AU

2 nov. 2025, 20:35 UTC

Câștiguri

Westpac FY CET1 Level 2 Capital Ratio 12.5% Vs. 12.5%>WBC.AU

2 nov. 2025, 20:35 UTC

Câștiguri

Westpac FY Net Interest Margin 1.94% Vs. 1.95%>WBC.AU

2 nov. 2025, 20:35 UTC

Câștiguri

Westpac Raises Dividend to A$0.77 Vs. A$0.76 >WBC.AU

2 nov. 2025, 20:34 UTC

Câștiguri

Westpac FY Rev A$22.38B Vs. A$21.59B >WBC.AU

2 nov. 2025, 20:33 UTC

Câștiguri

Westpac FY Net A$6.92B Vs. Net A$6.99B >WBC.AU

2 nov. 2025, 14:27 UTC

Câștiguri

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

2 nov. 2025, 14:25 UTC

Câștiguri

Warren Buffett Is Leaving Berkshire Hathaway in Great Shape for His Successor After Profit Results -- Barrons.com

Comparație

Modificare preț

Quanterix Corp Așteptări

Obiectiv de preț

By TipRanks

10.86% sus

Prognoză pe 12 luni

Medie 5.92 USD  10.86%

Maxim 7 USD

Minim 4.75 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruQuanterix Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

3 ratings

0

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

5.34 / 6.015Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Bullish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

142 / 373 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
help-icon Live chat